Logo

Acutis Diagnostics Gets FDA Emergency Use Authorization for COVID-19 RT-PCR Test

Jun 09, 2023 | staff reporter

NEW YORK — The US Food and Drug Administration on Tuesday granted Emergency Use Authorization for an RT-PCR-based test for COVID-19 infection developed by Acutis Diagnostics.

The SARS-CoV-2 Acutis Multiplex Assay is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal swab specimens from individuals suspected of having COVID-19.

The test may only be performed by Hicksville, New York-based Acutis, according to the FDA.

Earlier this year, Acutis struck a deal to incorporate Sophia Genetics analytics into a planned hereditary cancer sequencing assay.

Filed under

Molecular Diagnostics
Infectious Disease
COVID-19
PCR
Regulatory News & FDA Approvals
Business News
emergency use authorization
FDA
North America
Breaking News
The Scan

Cystatin C Plays Role in Immunosuppression, Cancer Immunotherapy Failure, Study Finds

A study in Cell Genomics provides insight into how glucocorticoids can lead to cancer immunotherapy failure via cystatin C production.

Aging, Species Lifespan Gene Expression Signatures Overlap

An Osaka Metropolitan University team reports in Nucleic Acids Research that transcriptional signatures of aging and maximum lifespan have similarities.

Splicing Subgroup Provides Protocols for Evaluating Splicing Variant Data

The group presents their approach on how to apply evidence codes to splicing predictions and other data in the American Journal of Human Genetics.

Single-Cell Transcriptomic Atlas of Mouse Cochlea to Aid Treatment Development

Researchers in PNAS conducted single-cell and single-nuclear sequencing of about 120,000 cells at three key timepoints in cochlear development to generate a transcriptomic atlas.